Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued [Yahoo! Finance]
NASCENT BIOTECH INC (NBIO)
NASDAQ:AMEX Investor Relations:
nascentbiotech.com/investor-relations
Company Research
Source: Yahoo! Finance
NORTH PALM BEACH, FL / ACCESSWIRE / January 9, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies focused on treating various cancers, announced today that the Company was featured in an independent research report by Marble Arch Research The report can be viewed on the Company web site at: https://www.nascentbiotech.com/marble-arch-research-what-is-pritumumab-and-how-it-works/ Nascent CEO Sean Carrick remarked, "We are pleased to be featured in this independent prospective of Nascent's investment potential. This report underscores our internal conviction that the Company's common stock is presently undervalued." Management highlights the research as corroborating its own sense that Pritumumab (PTB) is a potential breakthrough therapy in the $1.8 billion underserved brain cancer market. PTB has demonstrated safety and efficacy as well as a capacity to breach the bloo
Show less
Read more
Impact Snapshot
Event Time:
NBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIO alerts
High impacting NASCENT BIOTECH INC news events
Weekly update
A roundup of the hottest topics
NBIO
News
- Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run [Yahoo! Finance]Yahoo! Finance
- Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing RunAccesswire
- Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System [Yahoo! Finance]Yahoo! Finance
- Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery SystemAccesswire
- Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates [Yahoo! Finance]Yahoo! Finance
NBIO
Sec Filings
- 4/10/24 - Form 4
- 4/10/24 - Form 4
- 4/10/24 - Form 4
- NBIO's page on the SEC website